戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 etting to improve treatment of patients with kidney tumor.
2 WT) is a genetically heterogeneous childhood kidney tumor.
3 ely on the expression profile in the primary kidney tumor.
4 d renal oncocytoma are closely related, rare kidney tumors.
5  TBK1 kinase activity may slow the growth of kidney tumors.
6 ibrated using in vivo data from prostate and kidney tumors.
7 served in both TFEB- and TFE3-mediated human kidney tumors.
8 tomatous disease marked by mitochondria-rich kidney tumors.
9 ssic indications of hereditary and bilateral kidney tumors.
10 grams dictate major phenotypic attributes of kidney tumors.
11 egulators in a large cohort of primary human kidney tumors.
12  mediates POX/PRODH down-regulation in human kidney tumors.
13 ll WT samples analyzed, in contrast to other kidney tumors.
14 ls may be a useful adjunct to RF ablation of kidney tumors.
15 istochemical analysis on 40 cases of primary kidney tumors.
16  with betaE2 developed target organ specific kidney tumors.
17 s observed in two murine models of pediatric kidney tumors.
18 sion is altered in several breast, lung, and kidney tumors.
19 rimary breast tumors, pancreatic tumors, and kidney tumors.
20 for metastatic pancreatic neuroendocrine and kidney tumors.
21 nth decade of life; she has no pancreatic or kidney tumors.
22 l dominant disorder predisposing carriers to kidney tumors.
23 specific promoters (Cdh16 or Pax8) to induce kidney tumors.
24  cellular origin of 1300 childhood and adult kidney tumors.
25                                              Kidney tumors account for about 3% of tumors in adults.
26  an essential surgical approach to the small kidney tumor and provides equivalent local tumor control
27  prone to lung adenocarcinoma, lymphoma, and kidney tumor and that PCBP4-deficient mouse embryo fibro
28 en was identified in large amount within the kidney tumor and the bowel metastases.
29 he application of this UDD approach to treat kidney tumors and deliver other drugs such as doxorubici
30 oncogene ABL1 is upregulated in FH-deficient kidney tumors and drives a metabolic and survival signal
31 r considerations when planning management of kidney tumors and help inform shared decision making bet
32 s characterized by hair follicle hamartomas, kidney tumors and spontaneous pneumothorax.
33 020 living kidney donors, 1363 patients with kidney tumor, and 314 patients with native kidney diseas
34 d clinically for treating advanced liver and kidney tumors, and also has shown efficacy against other
35 ent ELT3 cells, mutant Tsc2-associated mouse kidney tumors, and human lung lymphangioleiomyomatosis n
36      Subcellular fractionation of the liver, kidneys, tumor, and pancreas showed that the majority of
37           Precise diagnosis and subtyping of kidney tumors are imperative to optimize and personalize
38 rm oncologic outcomes after cryoablation for kidney tumors are satisfactory.
39 e laparoscopic approach in the management of kidney tumors are unequivocal and the role of laparoscop
40 emely reduced or undetectable in DES-induced kidney tumors as compared to its age-matched control kid
41 indicated that it is highly overexpressed in kidney tumors as part of a concerted gene coexpression p
42 ic alteration that was common in DES-induced kidney tumors as well as in its surrounding non-tumor ti
43 eptibility disease characterized by skin and kidney tumors, as well as cystic lung disease, which res
44 n differentiating benign and malignant solid kidney tumors based on the initial stage of the study.
45  for the del3 allele have a markedly reduced kidney tumor burden in comparison with conventional Tsc2
46  been postulated to mediate the induction of kidney tumors by estradiol in male Syrian hamsters.
47 ne that becomes biallelically inactivated in kidney tumors by second-hit mutations.
48 on of wild-type Rpb1 stimulated formation of kidney tumors by VHL(+) cells, and this effect was aboli
49 of five groups: (a) subcutaneous tumors, (b) kidney tumors, (c) lung tumors with blood flow, and (d)
50 ived-hiPSCs allows us to recapitulate a rare kidney tumor called angiomyolipoma (AML).
51 m both baby hamster kidney cells and a human kidney tumor cell line, suggesting that Tax enters the s
52        Introducing wild-type pVHL into human kidney tumor cell lines carrying endogenous mutant non-f
53         It is particularly effective against kidney tumor cell lines, with >250-fold higher anti-tumo
54 strate that iPSCs derived from Dox-withdrawn kidney tumor cells give rise to nonneoplastic kidney cel
55 ighest cytostatic effect against ovarian and kidney tumor cells.
56 ognize HLA-A*0201-positive HERV-E-expressing kidney tumor cells.
57 l molecular phenotype of a genomically quiet kidney tumor, clear cell papillary renal cell carcinoma
58 restingly, total AKT protein was elevated in kidney tumors compared to normal kidney tissue, but with
59 h the application to the Cancer Genome Atlas kidney tumor data and the HITChip atlas data, PermFIT de
60 ecause the surgical management of hereditary kidney tumors depends on the genetic and histologic subt
61  tumors, three different histologic types of kidney tumors developed in BHD(d/+) mice including oncoc
62                    The mechanisms leading to kidney tumor development remain uncharacterized and effe
63 rom RNA-Seq databases, we found that patient kidney tumors exhibited increased CerS2 mRNA, which was
64 rt a role for PI3K-AKT pathway activation in kidney tumor formation caused by loss of BHD and suggest
65  led to both mTORC1 and mTORC2 activation in kidney tumors from BHD(d/+) mice and human BHD patients.
66 TSC1-TSC2 complex in cell culture models and kidney tumors from both Tsc2(+/-) mice (adenoma) and TSC
67  nucleocapsid (N) protein inhibits colon and kidney tumor growth and metastasis through the N-termina
68 y prove to be an effective way of inhibiting kidney tumor growth.
69 from Streptomyces achromogenes to induce new kidney tumors in BALB/c mice.
70 activated in both human BHD renal tumors and kidney tumors in BHD(d/+) mice.
71 l pediatric cancers and more than 95% of all kidney tumors in children.
72   Hyperphosphorylation of S6 is also seen in kidney tumors in the heterozygote mice, suggesting that
73 mallest coagulation diameter was observed in kidney tumors in the presence of blood flow (7.3 mm +/-
74  or multiple doses of streptozotocin induced kidney tumors in up to 25% of mice by 50-90 weeks of age
75                 Elimination of blood flow in kidney tumors increased coagulation diameter to 10.3 mm
76 xposed non-tumor kidney tissue, and in frank kidney tumors indicate that these genetic aberrations ar
77 omas at high frequency, but the incidence of kidney tumors is somewhat lower than in Tsc2 heterozygot
78    The etiology of Wilms tumor, an embryonic kidney tumor, is genetically heterogeneous.
79 isposition to Wilms' tumor (WT), a childhood kidney tumor, is inherited as an autosomal dominant trai
80  methodological and standardized analysis of kidney tumor location.
81 posed that allow for objective assessment of kidney tumor location.
82                Using an inducible orthotopic kidney tumor model, we demonstrate that YAP/TAZ silencin
83 A4, and POSTN) showed elevated expression in kidney tumor (n = 523) compared to normal (n = 100).
84 emia, Hodgkin disease, non-Hodgkin lymphoma, kidney tumor, neuroblastoma, soft-tissue sarcoma, or mal
85    We analysed the expression profiles of 70 kidney tumors of different histological subtypes to dete
86 in humans leads to Wilms' tumor, a pediatric kidney tumor, or other kidney diseases, such as Denys-Dr
87 d detrimental to the long-term health of the kidney tumor patient.
88 cally, early detection of small asymptomatic kidney tumors presages better patient outcome.
89 dissected whole exomes from 12 patients with kidney tumors, prior to validation using spatial transcr
90 d growth rates of other transplantable mouse kidney tumors), propensity for lung metastases, and hype
91  physicochemical properties, solubility, and kidney:tumor ratio while maintaining potency (6; IC(50)
92 urine specimens obtained in 50 patients with kidney tumors, representing all major histological types
93 med a neuroblastoma resection, 170 (55.2%) a kidney tumor resection, and 123 (39.9%) an operation to
94 , or 51% reduction in the volume of SN12-PM6 kidney tumors, respectively.
95             Applied to RNA-seq data from 524 kidney tumor samples, PLASMA achieves a greater power at
96 elanomas (SIR = 2.93, 95% CI: 2.23-3.78) and kidney tumors (SIR = 1.91, 95% CI: 1.27-2.76), primarily
97 ved in several glioma, breast, prostate, and kidney tumor specimens or cell lines.
98 1 family was highest in WT relative to other kidney tumor subtypes.
99  identified a reduced expression of BCCIP in kidney tumor, suggesting a role of BCCIP in cancer etiol
100 diagnosis, ranging from 4.0 years (6.0%) for kidney tumor survivors to more than 17.8 years (> or =28
101               Partial nephrectomy for larger kidney tumors (T1b) has gained widespread acceptance in
102 cer syndromes can lead to multiple bilateral kidney tumors that occur at a younger age than do nonher
103                     As observed in human BHD kidney tumors, three different histologic types of kidne
104                        When samples of human kidney tumor tissue were compared with samples of normal
105  T(RM) cell frequencies were not elevated in kidney tumor tissue, but they coexpressed PD-1 and TOX a
106 n that found for heparan sulfate from either kidney, tumor tissue, or growth plate aggrecan.
107                    With the exception of the kidneys, tumor-to-tissue and tumor-to-blood ratios were
108   Finally, unbiased analysis of TCGA primary kidney tumor transcriptomes confirms a positive correlat
109             Moreover, except for a subset of kidney tumors, tuberin was expressed in both human and m
110                                         In a kidney tumor, we identify 924 DCI genes involved in cell
111            Focusing on breast and clear-cell kidney tumors, we report the existence of key metabolic

 
Page Top